Hal Mackins News Today

Cancer Research Horizons, the innovation engine at the core of the world's largest private funder of cancer research, Cancer Research UK, is partnering with Turbine,* a tech-enabled biotech leveraging

– CBX-12 has potential to improve efficacy and reduce toxicity over systemic topoisomerase inhibitors –– Deal reflects Exelixis’ strategic focus on expanding its clinical pipeline and building upon its growing biotherapeutics expertise –ALAMEDA, Calif. & NEW HAVEN, Conn.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXE...

— IND filing for ADU-1805 expected in Q1 2023, providing Exelixis with an opportunity to expand its clinical pipeline —— ADU-1805 may have broad applicability across multiple tumor types, including solid tumors —ALAMEDA, Calif. & ROTTERDAM, The Netherlands--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Sairopa...

– Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu’s STING agonist technology, which has best-in-class potential –ALAMEDA, Calif. & KRAKOW, Poland--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and...

Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu's STING agonist technology, which

ALAMEDA, Calif. & LUND, Sweden--(BUSINESS WIRE)--Jun 16, 2022--

- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent's proprietary immuno-oncology (IO) screening

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform - Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics

Press release content from Business Wire. The AP news staff was not involved in its creation. Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline March 8, 2021 GMT ALAMEDA, Calif. & SHANGHAI--(BUSINESS WIRE)--Mar 8, 2021-- Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (“WuXi Bio”) (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansi...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 8, 2021--